undamentalytics Newsletter

Freeman Kevin D: insider trades

Director at Galectin Therapeutics Inc. 13 open-market purchases and no sales not made under a pre-set plan, reported from December 8, 2017 to December 23, 2025.

Would copying Freeman Kevin D’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. None of their purchases could be priced, so there is no copy portfolio. None of these trades can be measured yet: either the window after the report has not finished or the share price was under $5 when it was reported.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Freeman Kevin D: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Galectin Therapeutics Inc GALT —130December 8, 2017December 23, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
December 23, 2025December 23, 2025 GALT Purchase $19,525 not yetnot yetnot yet
July 18, 2025July 17, 2025 GALT Purchase $14,500 not yetnot yetnot yet
October 16, 2024October 16, 2024 GALT Purchase $27,000 not yetnot yetnot yet
October 31, 2022October 28, 2022 GALT Purchase $14,100 not yetnot yetnot yet
December 15, 2021December 6, 2021 GALT Purchase $11,400 not yetnot yetnot yet
December 6, 2021December 6, 2021 GALT Purchase $11,700 not yetnot yetnot yet
October 19, 2021October 19, 2021 GALT Purchase $10,110 not yetnot yetnot yet
September 23, 2021September 23, 2021 GALT Purchase $11,640 not yetnot yetnot yet
April 6, 2021April 5, 2021 GALT Purchase $10,200 not yetnot yetnot yet
September 9, 2020September 4, 2020 GALT Purchase $12,850 not yetnot yetnot yet
November 18, 2019November 15, 2019 GALT Purchase $10,080 not yetnot yetnot yet
June 3, 2019May 31, 2019 GALT Purchase $39,102 not yetnot yetnot yet
December 8, 2017December 7, 2017 GALT Purchase $13,696 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Freeman Kevin D traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.